BioCentury
ARTICLE | Product Development

Beyond 'me better'

March 5, 2007 8:00 AM UTC

Osteoporosis represents one of the paradoxes of modern drug development, where a huge market and the success of current treatments provides few incentives for novel approaches, even though the relatively small number of therapeutic alternatives suffer side effects ranging from the merely inconvenient to the fairly serious.

Indeed, the bisphosphonates, which block bone resorption, have now surpassed $5 billion in annual sales. But they are associated with burdensome compliance requirements as well as GI problems and osteonecrosis of the jaw...